Raising of funds
TORNTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.1 pts more than Nifty 100 and 0.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Torrent Pharmaceuticals reported strong FY26 standalone results with revenue of ₹10,498 crores (up 10.7% YoY) and net profit of ₹2,192 crores (up 16.1% YoY). The Board has recommended shareholder approval for raising up to ₹5,000 crores via Qualified Institutional Placement (QIP) or other modes. A final dividend of ₹9 per share was recommended, adding to the ₹29 interim dividend already paid, totaling ₹38 per share for FY26. The company completed its ₹12,537 crore acquisition of J.B. Chemicals & Pharmaceuticals (JB Pharma) in January 2026, gaining control over a major generic pharma player. Borrowings increased significantly to fund the acquisition, with debt equity ratio rising to 1.68 from 0.34 previously.
The large QIP authorization signals potential equity dilution ahead. The JB Pharma acquisition substantially increases scale but significantly raises leverage. Shareholders can expect dividend income but should monitor the dilutive QIP impact on their stake.